A Phase 3 interventional study of Placebo and Dupilumab SAR231893 in Atopic Dermatitis, sponsored by Sanofi. Completed at 19 sites in Japan. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 27th largest by enrollment, is one of 5 that started in 2021, is one of 11 in phase 3, and was the 30th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 6 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
43 studies in Dermatitis, Atopic by Sanofi: 5 open now, 16 under way, 4 of them phase 3. Of 26 finished, 9 (35%) have results posted.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2021, is one of 8 in phase 3, and was the 10th registered.
Sanofi’s Dermatitis, Atopic studies by the year they started, since 2006.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Sanofi’s 43 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS)
Secondary Objective:
To evaluate the efficacy of dupilumab administered concomitantly with TCS. To assess the safety of dupilumab over 16 weeks of treatment when administered concomitantly with TCS in participants.
To assess immunogenicity as determined by the incidence, titer, and clinical impact of treatment-emergent anti-drug antibodies (ADA) to dupilumab over time in pediatric patients with atopic dermatitis (AD) (aged ≥6 months to \<18 years old) To assess the concentration of dupilumab in serum following administration concomitantly with TCS.
For participant who declines to enter open-lebal extension (OLE), the duration of the study for each participant is approximately 33 weeks (including screening and follow-up) For participant choosing enter OLE, the duration is approximately 21 weeks (including screening) plus 3 years OLE period or until approval of the indication in Japan whichever is sooner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Japanese and ≥6 months to \<18 years of age, at the time of signing the and/or assent.
Diagnosis of AD according to the American Academy of Dermatology consensus criteria at screening visit.
Chronic AD diagnosed at least 1 year prior to the screening visit (for participants between 6 months to \<1 year of age, the requirement is to have had chronic AD for 3 months).
(Investigator's Global Assessment) IGA ≥ 3 at screening and baseline visits. (Eczema Area and Severity Index) EASI ≥16 at screening and baseline visits. Baseline peak pruritus Numerical Rating Scale (NRS) average score for maximum itch intensity ≥4 for participants ≥12 to \<18 years of age.
Baseline worst itch NRS or worst scratch/itch NRS weekly average score for maximum itch or scratch/itch intensity ≥4 for participants ≥6 months to \<12 years of age.
Body surface area (BSA) of AD involvement >10% at screening and baseline visits.
With documented recent history (within 6 months before the baseline visit) of inadequate response to topical AD medication(s).
At least 11 (of a total of 14) applications of a stable dose of topical emollient (moisturizer) twice daily immediately before the baseline visit.
Willing and able to comply with all clinic visits and study-related procedures. Participant, either alone or with help of parents/legal guardians (for 6 years old to less than18 years of age) or parents/caregiver or legal guardians (for 6 months to less than 6 years of age) as appropriate, must be able to understand and complete study-related questionnaires.
Body weight ≥5 kg at baseline. use by female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion criteria:
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the baseline visit or during the screening period.
Known or suspected immunodeficiency, including history of invasive opportunistic infections Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated TB will be excluded from the study unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist.
Known history of (HIV)-1 and HIV-2 infection or HIV seropositivity at the screening
Participants with any of the following result at the screening:
Presence of skin comorbidities that may interfere with study assessments History of within 5 years before the baseline visit History of systemic or anaphylaxis to dupilumab or any other biologic therapy.
Known or suspected alcohol and/or drug abuse. Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection.
Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.
Participant with any other medical or psychological condition including relevant laboratory or (ECG) abnormalities at screening Exposure to another systemic or topical investigative drug within a certain time period prior to Visit 1 (screening), Having used any of /immunomodulating drugs and phototherapy within 4 weeks before the screening visit.
Past Treatment with biologics as follows:
History of important side effects to medium potency TCS Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit.
Either intravenous immunoglobulin therapy and/or plasmapheresis within 30 days prior to screening visit.
Planned or anticipated use of any prohibited medications and procedures during screening and study treatment period.
Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period Participation in a prior dupilumab clinical study or have been treated with commercially available dupilumab.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double dose on day1 and followed by single dose every 2 weeks or single dose every 4 weeks
Drug: Dupilumab SAR231893
Double dose on day1 and followed by single dose every 2 weeks or single dose every 4 weeks
Drug: Placebo
Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% improvement from baseline EASI)
The EASI is a composite index with scores ranging from 0 to 72.Higher scores indicates worse condition
Time frame: At Week 16
Percent change in EASI score
The EASI is a composite index with scores ranging from 0 to 72.Higher scores indicates worse condition
Time frame: From baseline to week 16
Percent change in weekly average of daily worst itch numerical rating scale (NRS) for participants aged ≥6 years to <12 years old
The worst itch NRS is a simple assessment tool those participants ≥6 years old to \<12 years old will use to report the intensity of their pruritus (itch). This is an 11-point scale (0 to 10) in which 0 indicates no itching while 10 indicate worst itching possible.
Time frame: From baseline to week 16
Proportion of participants with Investigator's Global Assessment (IGA) 0 or 1
The IGA is an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe)
Time frame: At Week 16
Percent change in weekly average of daily worst peak pruritus NRS for participants aged ≥12 years to <18 years old
The peak pruritus NRS is a simple assessment tool that participants ≥ 12 to \<18 years old will use to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the' worst itch imaginable'
Time frame: From baseline to week 16
Percent change in weekly average of daily worst scratch/itch NRS for participants aged ≥6 months to <6 years old
The worst scratch/itch NRS is a simple assessment tool those participants ≥6 years old to \<6 years old range from 1 to 10 in which 0 indicates no itching while 10 indicate worst itching possible
Time frame: From baseline to week 16
Percent change for intensity of pruritus
The intensity is assessed by numerical rating scale ranging from 0 to 10 which higher scale indicate worse itch condition
Time frame: From baseline to week 16
Proportion of participants with EASI-50 (≥50% improvement from baseline)
The EASI is a composite index with scores ranging from 0 to 72.Higher scores is worse condition
Time frame: At Week 16
Proportion of participants with EASI-90 (≥90% improvement from baseline)
The EASI is a composite index with scores ranging from 0 to 72.Higher scores is worse condition
Time frame: At Week 16
Change in percent body surface area (BSA) affected by atopic dermatitis (AD)
BSA affected by atopic dermatitis will be assessed for each major section of the body (head, trunk, arms, and legs).
Time frame: From baseline to week 16
Change in Children's Dermatology Life Quality Index (CDLQI) (≥4 years)
The CDLQI is a validated questionnaire designed to measure the impact of skin disease on the Quality of Life. The higher the score, the greater the impact is on the quality of life
Time frame: From baseline to week 16
Change in Infants' Dermatitis Quality of Life Index (IDQOL) (<4 years)
The IDQOL is a validated questionnaire developed to measure the impact of skin disease on the QOL of infants and preschool children \<4 years of age wil completed by the child's parent or caregiver. The higher the score, the greater the impact is on the quality of life. -
Time frame: From baseline to week 16
Change in Patient Oriented Eczema Measure (POEM)
The POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire used to assess disease symptoms with a scoring system of 1 to 28. The higher score, the higher morbidity
Time frame: From baseline to week 16
Change in weekly average of daily worst peak pruritus NRS for participants aged ≥12 years to <18 years old
The peak pruritus NRS is a simple assessment tool that participants ≥ 12 to \<18 years old will use to report the intensity of their pruritus (itch) ranges from 0 to 10 with 1 being 'no itch' and 10 being the' worst itch imaginable'
Time frame: From baseline to week 16
Change in weekly average of daily worst itch NRS for participants aged ≥6 years to <12 years old
The worst itch NRS is a simple assessment tool those participants ≥6 years old to \<12 years old range from 1 to 10 in which 1 indicates no itching while 10 indicate worst itching possible -
Time frame: From baseline to week 16
Change in weekly average of daily worst scratch/itch NRS for participants aged ≥6 months to <6 years old
The worst scratch/itch NRS is a simple assessment tool those participants ≥6 years old to \<12 years old range from 1 to 10 in which 1 indicates no itching while 10 indicate worst itching possible
Time frame: From baseline to week 16
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESI) From Baseline to 16 Weeks of Treatment
Time frame: Baseline (Day 1) to Week 16
Number of Participants With Skin-Infection TEAEs (Excluding Herpetic Infections) From Baseline to 16 Weeks of Treatment
Time frame: Baseline (Day 1) to Week 16
Number of Participants With TEAEs, SAEs, and AESI From Baseline of open-label extension (OLE) Through the Last Study Visit
Time frame: Week 16 to Week 116
Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) to Dupilumab Over Time in Pediatric Participants with AD (Aged ≥6 Months to <18 Years old)
Time frame: Baseline (Day 1) to Week 116
Serum Concentration of Dupilumab up to Week 116
Time frame: Pre-dose at Baseline (Day 1), and Weeks 4, 12, 16, 24, 32, 52, 68, 92, and 116
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jan 2021 to primary completion in Dec 2021, 10 months.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 10 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab